Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Alice Chia-Chi Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2505-959X; OpenAlex author ID A5000216315, A5104097200, A5152879489, A5158359353; NIH RePORTER profile ID 15948925. Sources: ClinicalTrials.gov.

Their work

Papers
57 (first author 4, last author 12)
Trials
1 (principal investigator on 1)
Grants
1
Labs led
2
Collaborators
221
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 5 papers · 2022: 8 papers · 2023: 4 papers, 1 trial · 2024: 12 papers · 2025: 12 papers · 2026: 10 papers, 1 grant

Papers 50 of 57

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. First author DOI 10.1001/jamasurg.2026.2988↗
  2. Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model. Co-author DOI 10.1016/j.jvir.2025.107908↗
  3. Genomic evolution of pancreatic cancer at single-cell resolution. Co-author DOI 10.1038/s41588-025-02468-9↗
  4. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  5. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  6. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  7. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  8. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  9. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  10. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  11. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.70088↗
  12. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  13. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  14. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  15. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  16. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  17. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
  18. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
  19. Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. Last author DOI 10.1200/op-24-00528↗
  20. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Last author DOI 10.1245/s10434-025-17199-8↗
  21. ASO Author Reflections: Shifting Paradigms in the Management of Locally Advanced Pancreatic Cancer with Ablative Radiation. First author DOI 10.1245/s10434-025-17343-4↗
  22. Radiomics in sporadic microsatellite instable, mismatch repair deficient and Lynch syndrome-associated pancreatic ductal adenocarcinoma: a pilot study. Last author DOI 10.3389/fonc.2025.1584167↗
  23. Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer. First author DOI 10.1016/j.hoc.2024.01.004↗
  24. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Co-author DOI 10.1016/j.pan.2024.05.515↗
  25. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surg… Co-author DOI 10.1093/bjs/znae033↗
  26. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  27. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  28. Treatment Patterns and Outcomes in Pancreatic Cancer: A Comparative Analysis of Ontario and the USA. Last author DOI 10.1245/s10434-023-14375-6↗
  29. ASO Author Reflections: Improving Outcomes and Minimizing Variability in Pancreatic Cancer Care: A Study of Ontario and the United States. First author DOI 10.1245/s10434-023-14463-7↗
  30. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… Co-author DOI 10.1245/s10434-023-14680-0↗
  31. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Co-author DOI 10.1245/s10434-023-14815-3↗
  32. CT Surveillance for Local Recurrence After Pancreatic Cancer Resection: Evaluation of Imaging Findings From the SAR Disease-Focused Panel Consensus Statement. Co-author DOI 10.2214/ajr.24.31563↗
  33. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study. Co-author DOI 10.3390/curroncol31050194↗
  34. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  35. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  36. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  37. Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration. Co-author DOI 10.1117/1.jmi.10.3.036002↗
  38. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-22-3089↗
  39. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  40. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  41. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  42. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Co-author DOI 10.1093/jnci/djac018↗
  43. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria: Not So Simple. Co-author DOI 10.1097/sla.0000000000005504↗
  44. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/xcs.0000000000000212↗
  45. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Last author DOI 10.1177/0003134821989050↗
  46. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Last author DOI 10.6004/jnccn.2022.7008↗
  47. Treatment patterns and survival in patients with early-onset pancreatic cancer. Last author DOI 10.1002/cncr.33664↗
  48. A Risk Score Model for Locoregional Recurrence Following Upfront Surgery for Pancreatic Adenocarcinoma: Implications for Adjuvant Therapy. Co-author DOI 10.1016/j.clon.2021.03.007↗
  49. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Last author DOI 10.1097/sla.0000000000005080↗
  50. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗

Trials 1

  1. A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) Principal investigator NCT05851924↗

Grants 1

  1. Biostatistics Core P50CA257881↗

Closest collaborators

The 25 strongest of 221 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 26 shared papers, 1 shared grant, 2019–2026 · strength 5.29
  2. William R. Jarnagin · 22 shared papers, 2021–2026 · strength 3.81
  3. Vinod P. Balachandran · 13 shared papers, 1 shared grant, 2021–2026 · strength 2.88
  4. Michael Ian D'Angelica · 17 shared papers, 2021–2026 · strength 2.79
  5. Jeffrey A. Drebin · 16 shared papers, 2021–2026 · strength 2.68
  6. Kevin C. Soares · 15 shared papers, 2021–2026 · strength 2.60
  7. Bas Groot Koerkamp · 13 shared papers, 2021–2026 · strength 2.45
  8. Marc G. Besselink · 12 shared papers, 2021–2026 · strength 2.36
  9. Matthew H. G. Katz · 11 shared papers, 2022–2026 · strength 2.25
  10. Amer H. Zureikat · 11 shared papers, 2022–2026 · strength 2.25
  11. Ching-Wei David Tzeng · 11 shared papers, 2022–2026 · strength 2.25
  12. Quisette P. Janssen · 12 shared papers, 2021–2026 · strength 1.99
  13. Wungki Park · 11 shared papers, 2021–2026 · strength 1.97
  14. Anna M. Varghese · 12 shared papers, 2021–2026 · strength 1.96
  15. T. Peter Kingham · 11 shared papers, 2021–2025 · strength 1.71
  16. Laura R. Prakash · 9 shared papers, 2022–2026 · strength 1.71
  17. Christine A. Iacobuzio–Donahue · 5 shared papers, 1 shared grant, 2023–2026 · strength 1.63
  18. Marinela Capanu · 5 shared papers, 1 shared grant, 2024–2026 · strength 1.56
  19. Kenneth H. Yu · 9 shared papers, 2021–2026 · strength 1.51
  20. Esther N. Dekker · 6 shared papers, 2024–2026 · strength 1.41
  21. Alessandro Paniccia · 7 shared papers, 2022–2026 · strength 1.40
  22. Marsha Reyngold · 7 shared papers, 2021–2026 · strength 1.22
  23. Olca Baştürk · 3 shared papers, 1 shared grant, 2025–2026 · strength 1.18
  24. Christopher H. Crane · 7 shared papers, 2021–2026 · strength 1.16
  25. Deesje Doppenberg · 6 shared papers, 2022–2024 · strength 1.00

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.